Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants

Authors:
  • OEOgo Egbuna
    Ogo Egbuna
  • BZBrandon Zimmerman
    Brandon Zimmerman
  • GMGeorge Manos
    George Manos
  • AFAnne Fortier
    Anne Fortier
  • MCMadalina C. Chirieac
    Madalina C. Chirieac
  • LDLeslie A. Dakin
    Leslie A. Dakin
  • DFDavid J. Friedman
    David J. Friedman
  • KBKate Bramham
    Kate Bramham
  • KCKirk Campbell
    Kirk Campbell
  • BKBertrand Knebelmann
    Bertrand Knebelmann
  • LBLaura Barisoni
    Laura Barisoni
  • RFRonald J. Falk
    Ronald J. Falk
Top Cited Papers
Publisher website
Google Scholar
Abstract
Persons with toxic gain-of-function variants in the gene encoding apolipoprotein L1 (APOL1) are at greater risk for the development of rapidly progressive, proteinuric nephropathy. Despite the known genetic cause, therapies targeting proteinuric kidney disease in persons with two APOL1 variants (G1 or G2) are lacking. We used tetracycline-inducible APOL1 human embryonic kidney (HEK293) cells to assess the ability of a small-molecule compound, inaxaplin, to inhibit APOL1 channel function. An APOL1 G2-homologous transgenic mouse model of proteinuric kidney disease was used to assess inaxaplin treatment for proteinuria. We then conducted a single-group, open-label, phase 2a clinical study in which inaxaplin was administered to participants who had two APOL1 variants, biopsy-proven focal segmental glomerulosclerosis, and proteinuria (urinary protein-to-creatinine ratio of ≥0.7 to 2 of body-surface area). Participants received inaxaplin daily for 13 weeks (15 mg for 2 weeks and 45 mg for 11 weeks) along with standard care. The primary outcome was the percent change from the baseline urinary protein-to-creatinine ratio at week 13 in participants who had at least 80% adherence to inaxaplin therapy. Safety was also assessed. In preclinical studies, inaxaplin selectively inhibited APOL1 channel function in vitro and reduced proteinuria in the mouse model. Sixteen participants were enrolled in the phase 2a study. Among the 13 participants who were treated with inaxaplin and met the adherence threshold, the mean change from the baseline urinary protein-to-creatinine ratio at week 13 was -47.6% (95% confidence interval, -60.0 to -31.3). In an analysis that included all the participants regardless of adherence to inaxaplin therapy, reductions similar to those in the primary analysis were observed in all but 1 participant. Adverse events were mild or moderate in severity; none led to study discontinuation. Targeted inhibition of APOL1 channel function with inaxaplin reduced proteinuria in participants with two APOL1 variants and focal segmental glomerulosclerosis. (Funded by Vertex Pharmaceuticals; VX19-147-101 ClinicalTrials.gov number, NCT04340362.).
Funding Information
  • Vertex Pharmaceuticals Incorporated

This publication has 38 references indexed in Scilit: